drugset / Trial / NCT07326371
Glofitamab Combined With CAR-T Therapy in R/R DLBCL
NaSingle-groupOpen-labelTreatment
Summary
This study is a single-center, open-label, prospective study aimed at evaluating the efficacy and safety of Glofitamab combined with CAR-T therapy in patients with high-risk relapsed/refractory large B-cell lymphoma.
Timeline
- Start
- 2026-03
- Primary completion
- 2027-07
- Completion
- 2029-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Axicabtagene Ciloleucel | Cell therapy | — | Intravenous |
| Subject | Glofitamab | Monoclonal antibody | — | Intravenous |
| Subject | Relmacabtagene Autoleucel | Cell therapy | — | Intravenous |
| Background | Obinutuzumab | Monoclonal antibody | 1000 mg | Intravenous |